Evidence map›Paper›PMID 35846183›Full record

ArticleEJHaem2022

Leg-type form of idiopathic multicentric Castleman disease associated with severe lower extremity chronic venous/lymphatic disease.

Thomas Ballul, Nabil Belfeki, Adèle de Masson, Véronique Meignin, Paul-Louis Woerther, Antoine Martin, Elsa Poullot, Alain Wargnier, Jehane Fadlallah, Margaux Garzaro and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 1 country.

Thomas BallulClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Nabil BelfekiInternal Medicine Department Centre hospitalier de Melun Melun France.
Adèle de MassonDermatology Department Université de Paris Paris France.
Véronique MeigninPathology Department Hôpital Saint Louis Université de Paris Paris France.
Paul-Louis WoertherBacteriology and Virology Department Hôpital Henri Mondor Créteil France.
Antoine MartinPathology Department Hôpital Avicenne Université Sorbonne Paris Nord Bobigny France.
Elsa PoullotPathology Department Hôpital Henri Mondor Université Paris-Est Créteil Créteil France.
Alain WargnierBacteriology Department Hôpital Saint Louis Université de Paris Paris France.
Jehane FadlallahClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Margaux GarzaroClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Marion MalphettesClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.ORCID https://orcid.org/0000-0002-9888-2528
Claire FieschiClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Lucas MaisonobeClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Hayat BensekhriInternal Medicine Department Groupe Hospitalier Nord Essonne Longjumeau France.
Hélène GuillotInternal Medicine Department Hôpital Robert Ballanger Université Sorbonne Paris Nord Aulnay-Sous-Bois France.
Rémi BertinchampClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Marie JachietDermatology Department Université de Paris Paris France.
Justine PoirotINSERM U976 HIPI, Hôpital Saint Louis Université de Paris Paris France.
Lionel GalicierClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.
Eric OksenhendlerClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.ORCID https://orcid.org/0000-0001-8588-7138
David BoutboulClinical Immunology Department Hôpital Saint Louis, Université de Paris Paris France.ORCID https://orcid.org/0000-0002-5006-8279
Université Paris Cité · FRInserm · FRSorbonne Université · FRCentre Hospitalier Sud-Essonne Dourdan-Etampes · FRCentre Hospitalier Universitaire Henri-Mondor · FRMelun Hospital · FRUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disease of unknown etiology. Deciphering mechanisms involved in CD pathogenesis may help improving patients' care. Six cases of stereotyped sub-diaphragmatic iMCD affecting lower limb-draining areas and associated with severe and often ulcerative lower extremity chronic dermatological condition were identified in our cohort. Pathological examination revealed mixed or plasma-cell type MCD. In three patients, shotgun metagenomics failed to identify any pathogen in involved lymph nodes. Antibiotics had a suspensive effect while rituximab and tocilizumab failed to improve the condition. This novel entity requires a specific approach and exclusion of potentially harmful immunomodulation.

Indexed as

Castleman diseasechronic venous diseaselymphedema

Identifiers

PMID35846183
PMCPMC9175857
OpenAlexW4200121262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.